Clinical Trial

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia

Study acronym: RADOVAN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation. The treatment of negative symptoms with the same protocol in schizophrenia is considered as possible effective. Theta burst stimulation is a new protocol which is characterized by shorter sessions showing first evidence that it's efficacy is comparable to the high-frequency rTMS. In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are evaluated.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-03-20; most recent amendment 2025-09-18.
Status change: Recruiting → Active, Not Recruiting 2024-09-13
Trial Details
NCT Number NCT04318977
Lead Sponsor University of Regensburg
Collaborators: University Hospital, Aachen, University Hospital Ostrava, Brno University Hospital
Conditions Negative Symptoms With Primary Psychotic Disorder, Schizophrenia
Enrollment 62 participants
Start Date 2020-02-01
Primary Completion 2024-08-14 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-19